Stock comparison
Genmab A/S
Vertex Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
VRTX
Vertex Pharmaceuticals
Market cap
$110.28B
Sector
Healthcare
Overall winner
Vertex Pharmaceuticals VRTX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | VRTX | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 64C | GMAB |
| Benjamin Graham | 64C | 66D | VRTX |
| Philip Fisher | 48D | 70B | VRTX |
| Peter Lynch | 25F | 60C | VRTX |
| Joel Greenblatt | 76B | 55C | GMAB |
| Charlie Munger | 68C | 67D | GMAB |
| Terry Smith | 71C | 64C | GMAB |
Side-by-side metrics
| Metric | GMAB | VRTX |
|---|---|---|
| Market cap | $16.5B | $110.28B |
| P/E (TTM) | 6.2x | 25.6x |
| EV/EBIT | 12.0x | 22.6x |
| ROIC (TTM) | 43.78% | 17.74% |
| Gross margin | 93.88% | 86.28% |
| Net margin | 18.23% | 35.4% |
| Revenue CAGR 5y | -18.45% | 12.37% |
| EPS CAGR 5y | -23.48% | 14.2% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 25.6x+76%
- ROIC (TTM)43.78%vs 17.74%+59%
- EV/EBIT12.0xvs 22.6x+47%
- Debt / Equity0.1xvs 0.1x+28%
VRTX leads on
- Revenue CAGR 5y12.37%vs -18.45%+167%
- EPS CAGR 5y14.2%vs -23.48%+160%
- Market cap$110.28Bvs $16.5B+85%
- Net margin35.4%vs 18.23%+48%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.